AI-generated image
Contents
I want to tell you about a pharmaceutical sales representative I observed last month.
She walked into a pharmacy in Pretoria at 9:14 AM. She didn’t carry a product binder. She didn’t ask to speak with the pharmacist about a promotional offer. She didn’t mention a single product feature.
Instead, she opened her tablet, showed the pharmacist a dashboard, and said: “You’ve lost 23% of your diabetic patient base over the past four months. I can see exactly where they’re going, and I have a plan to bring them back.”
The pharmacist put down what he was doing. The conversation lasted 47 minutes.
She walked out with the largest order that pharmacy had placed in three years.
That is the pharmaceutical representative of 2030. And she is not selling. She is conducting.
The Orchestra Problem
Here is a number that should concern every pharmaceutical commercial director in Africa: 10x.
That is the typical variance between the best and worst performing representatives in a pharmaceutical sales force. Your top rep outsells your bottom rep by a factor of ten. Same products. Same territories. Same training. Same incentive scheme.
When I share this with executives, they nod. They have seen it. They have tried to fix it with training programmes, coaching initiatives, performance management systems. Some have resorted to mass terminations and rebuilds.
Nothing works. Not permanently.
And here is why: they are treating a systems problem as a people problem.
The variance is not about talent. It is about what happens before the rep walks through the door.
Think about it this way. An orchestra does not succeed because it recruits the best individual musicians. It succeeds because every musician plays from the same score, follows the same conductor, and arrives prepared for the same performance.
Your sales force is an orchestra playing without a conductor. Each musician is reading a different score. Some are playing last year’s music. Others are improvising. A few are playing in the wrong key entirely.
The result? Noise. Expensive noise.
What the Research Actually Says
I have spent two decades reading what academics have discovered about sales performance. Not the airport bookstore variety. The peer-reviewed, meta-analysed, replicated findings from journals most pharmaceutical executives have never encountered.
Here is what they found.
Verbeke, Dietz, and Verwaal (2011) conducted a comprehensive meta-analysis of sales performance drivers, examining studies spanning 26 years. The strongest predictor of sales success was selling-related knowledge (beta = .28). The second strongest was degree of adaptiveness (beta = .27).
Not personality. Not charm. Not even experience.
Knowledge and adaptation. The ability to know things the customer does not, and the ability to change approach based on what you learn.
Franke and Park (2006) analysed 155 samples representing more than 31,000 salespeople. They found that adaptive selling behaviour increases self-rated, manager-rated, and objective performance measures. Not one. All three.
Vinchur and colleagues (1998) found that the conscientiousness facet of “achievement striving” correlates with objective sales performance at r = .41 - a correlation stronger than most pharmaceutical interventions achieve in clinical trials.
But here is the finding that changed how I think about this industry entirely.
General cognitive ability - the thing we measure in aptitude tests and assume predicts everything - correlated with objective sales at r = .04.
Point zero four. Essentially zero.
Intelligence does not predict sales performance. Knowledge does. Adaptation does. Structured discipline does.
So why do most pharmaceutical companies still hire based on interview impressions, train based on product features, and measure based on call quantity?
Because they have not built the system that makes knowledge and adaptation possible.
The Rep as Conductor
In 2019, I stood at a whiteboard in our Johannesburg office and drew a picture that became the foundation of everything we do at Herbst Group.
On the left: the traditional pharmaceutical representative. A messenger carrying information from the company to the customer. Arrow pointing one direction. Product knowledge in. Prescription hopefully out.
On the right: something different. A figure standing at the centre of a complex web. Information flowing in from multiple sources. Insights flowing out to multiple stakeholders. The rep was not carrying messages. The rep was coordinating value.
Like a conductor in front of an orchestra.
The conductor does not play every instrument. The conductor ensures every instrument plays at the right time, in the right key, for the right audience. The conductor arrives prepared because someone has already analysed the score. The performance is delivered, not improvised.
We called it the Herbst Conductor model. And here is the practical difference.
The traditional pharmaceutical rep spends Monday morning planning the week. Pulling data. Analysing spreadsheets. Identifying which customers to see. Building call plans. That takes two to four hours of prime selling time every single week.
The Conductor rep receives a notification every Monday at 7 AM. It contains:
- A prioritised list of exactly which customers to see, ranked by opportunity size
- Specific product recommendations for each customer, based on their purchasing patterns
- Early warning alerts for accounts showing decline
- Performance context showing how the rep is tracking against benchmarks
The Conductor rep starts selling at 8 AM. The traditional rep starts selling at noon.
Multiply that difference across 200 selling days per year. Multiply it across a field force of 50 reps. You have just created the equivalent of 25 additional full-time selling resources without hiring anyone. That is mathematics, not theory.
The Technology Stack That Makes Conducting Possible
I need to be specific here, because specificity is what separates consulting theatre from actual execution.
The Conductor model requires four components working in concert.
Transaction Intelligence.
We built a platform called SNIPER (Sales Navigation Intelligence Platform Enabling Results). It ingests 12 to 24 months of transaction data, applies pattern recognition, and outputs prescriptive actions.
SNIPER identifies what we call “Hidden Champions”: customers with high potential who are currently under-served. It flags declining accounts before they churn completely. It recommends specific products for specific customers based on purchasing behaviour, not demographic assumptions.
Most importantly, it reveals where revenue hides and where it leaks. In one client engagement, we identified substantial annual revenue being lost through coverage gaps that the client’s best regional manager had no idea was happening.
Geographic Intelligence.
Her-Zone integrates multiple data layers: healthcare infrastructure, disease surveillance, demographics, commercial zones, travel patterns - built from South African sources and overlaid on commercial customer data.
When a Conductor rep opens Her-Zone, she does not see a map. She sees opportunity density. She sees travel optimisation. She sees where competitors win by default because nobody bothered to show up.
Weekly Delivery Mechanism.
Auto-Snipe takes the outputs from SNIPER and Her-Zone and delivers personalised weekly intelligence to every rep in the field. Right customers. Right products. Right conversation. Every Monday.
The rep does not analyse data. The rep receives insights. The rep acts.
Real-Time Visibility.
Executive dashboards provide executives with live revenue trends, customer health monitoring, and rep productivity tracking. No more waiting for month-end. No more manually compiled reports. No more surprises.
When these four components work together, something measurable happens. The variance between top and bottom performers shrinks. Not because the bottom performers suddenly become talented. Because the bottom performers finally have access to the same intelligence the top performers were generating through intuition and extra effort.
We do not make bad reps good. We make the system fair.
The 2030 Representative in Practice
Let me paint a more complete picture of what pharmaceutical selling looks like when the Conductor model is fully operational.
It is 6:47 AM on a Monday in April 2030. A pharmaceutical representative named Thandi opens her phone while drinking coffee. A notification from Auto-Snipe:
“Priority call this week: Apex Pharmacy, Sandton. Account has declined 31% over six months. Owner purchasing competitor products in categories where you have therapeutic superiority. Opportunity value: R340,000 annually. Recommended approach: clinical efficacy data for Product X. Owner responds to evidence-based arguments. Last positive interaction: August 2029.”
Thandi does not need to pull reports. She does not need to analyse spreadsheets. She does not need to guess.
She arrives at Apex at 10:30 AM. She does not open with “How’s business?” She opens with: “Johannes, I noticed something concerning in your purchasing patterns, and I wanted to talk through what might be happening.”
Johannes, the owner, looks up. Most reps ask him to stock more product. This one is asking about his business.
Thandi continues: “You have moved around R28,000 per month to a competitor in a category where our clinical outcomes are actually stronger. I am curious whether that was a deliberate choice or whether something went wrong on our end.”
Johannes puts down his pen.
It turns out there was a delivery issue six months ago. A complaint that was never resolved. A relationship that eroded through negligence, not competition.
Thandi opens Her-Zone on her tablet. She shows Johannes the patient demographic data for his catchment area. The disease prevalence. Why his location is specifically suited to the therapeutic category they are discussing.
Then she shows him clinical evidence. Not marketing materials. Evidence.
By the end of the conversation, Johannes has agreed to a trial order. Not because Thandi pushed. Because Thandi knew things Johannes did not, and those things were genuinely useful to his business.
Thandi leaves at 11:47 AM. Total time invested: 77 minutes. Value at stake: R340,000 in recovered annual revenue, and a relationship repaired.
The traditional rep would have made five calls in the same time. Shallow calls. Transactional calls. Calls that create activity reports but not business outcomes.
The Conductor made one call. It counted.
Why Most Pharmaceutical Companies Will Not Do This
Most pharmaceutical commercial directors will read this article, nod in agreement, and change nothing.
Here is why.
The Conductor model requires honesty about current performance. It requires admitting that call quantity reports are vanity metrics. It requires acknowledging that the territory structure inherited from a predecessor might be fundamentally broken. It requires confronting the possibility that some of your best performers are simply working harder, not smarter, and that advantage will disappear the moment they leave.
Most organisations are not ready for that conversation.
They prefer the comfortable fiction that training programmes will fix performance problems. That incentive scheme tweaks will close the 10x gap. That next quarter’s market research will finally reveal the insight they have been missing.
It will not.
The insight is not missing. The system is missing.
The Conductor Model and Human Dignity
I hear an objection occasionally: “Aren’t you reducing sales professionals to automatons? Where is the human skill?”
The opposite is true.
The traditional model reduces sales professionals to message carriers. Walk in, recite features, leave samples, record the call. That is not a profession. That is a delivery service with a bonus structure.
The Conductor model elevates sales professionals to consultants. Arrive informed. Listen actively. Adapt continuously. Deliver genuine value. Build relationships that compound over years.
The Conductor rep thinks. The Conductor rep advises. The Conductor rep exercises judgment.
Consider what happens when a rep arrives without adequate preparation. She improvises. She relies on rapport. She talks about weather and sports. She mentions product features when the conversation allows. She hopes something sticks.
That is not consultative selling. That is expensive socialising.
When the same rep arrives with intelligence, something different becomes possible. She can ask informed questions. She can offer insights the customer lacks. She can position herself as a resource worth 47 minutes of undivided attention rather than a distraction to be politely tolerated.
Kahneman and Tversky demonstrated - and won a Nobel Prize for it - that human beings are predictably irrational. We overweight certain outcomes. We feel losses roughly twice as intensely as equivalent gains. We anchor on irrelevant information.
The Conductor model does not fight these tendencies. It accounts for them. When a rep knows a customer is facing a 31% decline, she can frame recovery as loss prevention rather than sales growth. When a rep knows a competitor is winning through presence rather than superiority, she can target that specific vulnerability.
The psychology is built into the system. The rep does not need to remember the research. The rep needs to follow the plan.
The automation is not replacing human capability. It is creating space for human capability to matter.
What Changes by 2030
Let me make some specific predictions for pharmaceutical commercial operations in 2030. Not speculation - extrapolations from trends we are already observing.
Call quantity metrics will disappear. The organisations still measuring representatives by number of calls will be the organisations losing market share. Call quality, measured through outcome tracking, will replace call quantity entirely.
Territory design will become continuous. Static annual territory reviews will give way to dynamic rebalancing based on real-time opportunity data. Territories will flex monthly, not annually.
AI will handle preparation, humans will handle relationships. The insight generation currently requiring specialist analysts will be fully automated. Representatives will receive complete customer intelligence before every interaction. Their value will come from what they do with that intelligence, not from gathering it.
The 10x variance will narrow to a 2x variance. Not because the bottom performers improve dramatically. Because the system stops handicapping them. When everyone plays from the same score, the differences become about execution, not access.
Pharmaceutical companies will compete for Conductors. The representatives who can interpret intelligence, adapt approaches, and build trust will command premium compensation. Those who can only deliver messages will find their roles eliminated.
The Invitation
I have spent considerable words telling you what is possible. Here is what I want.
I want pharmaceutical commercial directors to stop tolerating the 10x variance as inevitable. It is not. It is a systems failure, and systems can be rebuilt.
I want field force leaders to measure what matters. Outcome per call, not calls per day. Revenue recovered, not samples distributed. Relationships deepened, not contacts logged.
I want sales representatives to demand better from their employers. Demand intelligence. Demand preparation. Demand the tools that allow professional skills to matter.
We have built the Conductor model over two decades. We have refined it through ongoing partnerships with clients who stayed because the results kept coming.
We do not promise transformation. We deliver documented improvements within 90 days. That is not marketing language. That is our operating standard.
Final Thought
The pharmaceutical representative of 2030 will walk into a pharmacy and have a conversation that would be impossible today.
Not because she is smarter. Not because she is more charming. Not because she trained harder or cares more or has more experience.
Because she arrived prepared. Because someone built the system that made preparation automatic. Because the orchestra finally has a conductor.
The representative I described at the beginning of this article is not hypothetical. She is real. She works for one of our clients. She closed the largest order in that pharmacy’s three-year history because she knew things the pharmacist did not, and those things were genuinely useful.
That is not selling. That is conducting.
And by 2030, it will be the only way pharmaceutical commercial excellence happens.
The governed data and zone intelligence that makes a rep a Conductor - that is what we build.
Dieter Herbst is CEO of Herbst Group, a pharmaceutical commercial excellence firm with ongoing embedded partnerships. Herbst Group’s methodologies include SNIPER, Her-Zone, Auto-Snipe, and the Herbst Conductor Framework.
“Precision beats volume. Every time.”
Listen to This Article
The Pharmaceutical Representative of 2030
Written by
Dieter Herbst
CEO at Herbst Group. Working with pharmaceutical commercial leaders across South Africa, Kenya, and Brazil to transform sales force effectiveness through evidence-based approaches.
Connect on LinkedIn